According to the 2019 American Association of Clinical Endocrinologists (AACE) guidelines, continuation of rhGH treatment is recommended without provocative GH testing if there is biochemical evidence of multiple pituitary hormone deficiencies (MPHDs) (≥3 pituitary hormone deficiencies) and low serum IGF-1 levels [<−2.0 SD score (SDS)] (34). This evidence concerns the gene GH1 and hypopituitarism.